Coloplast A/S (NASDAQ:CLPBY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Thursday.

According to Zacks, “Coloplast A/S develops and provides health care products and services. Its operating business segments consist of Chronic Care, Urology Care and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Urology Care segment offers urological products, including disposable products. The Wound and Skin Care segment covers the sale of wound and skin care products. Coloplast A/S is headquartered in Humlebaek, Denmark. “

Shares of Coloplast A/S (NASDAQ CLPBY) opened at 8.12 on Thursday. Coloplast A/S has a 12-month low of $6.14 and a 12-month high of $8.84.

ILLEGAL ACTIVITY WARNING: This story was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.dailypolitical.com/2017/09/22/coloplast-as-clpby-stock-rating-lowered-by-zacks-investment-research.html.

Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.